Study #2018-0006
Phase II Investigation of Adjuvant Combined Cisplatin and Radiation with Pembrolizumab in Resected HNSCC
MD Anderson Study Status
Not Accepting
Treatment Agent
Pembrolizumab, Cisplatin
Description
The purpose of this research study is to test the safety and the benefit of adding pembrolizumab (a therapy that activates the immune system to fight cancer) to standard of care treatment for head and neck cancer. The standard of care treatment will include surgery followed by radiation for 6 weeks. Some patients may also receive cisplatin as standard of care once a week for 6 weeks if the cancer is found to be "high risk". High risk includes cancer that was not completely removed (positive margins) or cancer that has invaded through the outer lining of your lymph nodes.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Head and Neck Cancer
Study phase:
Phase II
Physician name:
Maura Gillison
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-877-839-0558
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.